FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to internal diseases, and can be used to select personified prediction of clinical effectiveness of non-alcoholic fatty liver disease in patients with metabolic syndrome. Method of personified prediction of clinical effectiveness of non-alcoholic fatty liver disease in patients with ursodeoxycholic acid syndrome in a daily dosage of 15 mg per kg of body weight divided into 3 doses (after breakfast, after lunch and after dinner) in combination with Rosuvastatin 10 mg a day (after dinner) within 6 months includes determining initial values of alanine aminotransferase (ALT, units/l); level of C-reactive protein (CRP, mg/l); atherogenic index (AI) level; insulin resistance index (IR) level; level of diastolic arterial pressure (APd, mm Hg) and solving the discriminant equation: D=0.157×ALT+0.127×CRP+0.286×AI+0.515×IR+0.034×APd-10.948, where D is a discriminant function with its boundary value equal to zero, wherein if D is less than or equal to zero, a positive clinical outcome is predicted, and if D is greater than zero, a negative clinical outcome is predicted.
EFFECT: invention provides higher accuracy of personalized prediction of clinical effectiveness of non-alcoholic fatty liver disease.
1 cl, 2 ex
